1 / 46

Cancer-associated Thrombotic Disease

Reporter: CR 吳嘉芸 Supervisor: VS 邱宗傑. Cancer-associated Thrombotic Disease. Reporter: CR 吳嘉芸 Supervisor: VS 邱宗傑. Cancer-associated Thrombotic Disease. Outline. History Epidemiology Pathogenesis Thromboprophylaxis. Outline. History Epidemiology Pathogenesis Thromboprophylaxis.

santos
Download Presentation

Cancer-associated Thrombotic Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Reporter: CR 吳嘉芸 Supervisor: VS 邱宗傑 Cancer-associated Thrombotic Disease

  2. Reporter: CR 吳嘉芸 Supervisor: VS 邱宗傑 Cancer-associated Thrombotic Disease

  3. Outline • History • Epidemiology • Pathogenesis • Thromboprophylaxis

  4. Outline • History • Epidemiology • Pathogenesis • Thromboprophylaxis

  5. Cancer-associated Thrombosis The first report was published by the French physician Jean-BaptisteBouillaud in 1823

  6. Cancer-associated Thrombosis Widely quoted description by Armand Trousseau in 1865 Trousseau’s Syndrome migratory thrombophlebitis associated with an occult visceral malignancy

  7. Outline • History • Epidemiology • Pathogenesis • Thromboprophylaxis

  8. Epidemiology • About 20% - 30% of venous thromboembolism (VTE)are cancer- associated • Cancer patients have a 4 to 7-fold increased risk of VTE compared with the general population 【Blood 2013 122: 1712-1723】

  9. Type of Cancer VS. Risk of VTE 【Blood 2013 122: 1712-1723】

  10. Later stage of cancer, higher risk of VTE 【Blood 2013 122: 1712-1723】

  11. Cancer with VTE in Taiwan • 497,180 cancer patients, between 1997 to 2005, with a median follow-up of 21.3 months • Incidence: 185 events per 100,000 person-years • 11.5 times higher than the general population 【ThrombHaemost 2012; 108: 225–235】

  12. Cancer with VTE in Taiwan • 497,180 cancer patients, between 1997 to 2005, with a median follow-up of 21.3 months • Incidence: 185 events per 100,000 person-years • 11.5 times higher than the general population 【ThrombHaemost 2012; 108: 225–235】 【Blood 2013 122: 1712-1723】

  13. Cancer with VTE in Taiwan • 497,180 cancer patients, between 1997 to 2005, with a median follow-up of 21.3 months • Incidence: 185 events per 100,000 person-years • 11.5 times higher than the general population • The annual incidence in Taiwan is much lower than in Western populations 【ThrombHaemost 2012; 108: 225–235】

  14. Cancer with VTE in Taiwan 【ThrombHaemost 2012; 108: 225–235】

  15. Cancer with VTE in Taiwan 【ThrombHaemost 2012; 108: 225–235】

  16. Outline • History • Epidemiology • Pathogenesis • Thromboprophylaxis

  17. Pathogenesis • Mucin • Tissue Factor • Tumor Hypoxia • Cysteine Proteinase • Oncogene Activation

  18. 【Blood 2007 110: 1723-1729】

  19. 1 【Blood 2007 110: 1723-1729】

  20. Mucin • Trousseau’s syndrome associated with mucin-producing carcinomas • Glycosylated secretory products of epithelial cells • ligands for the selectins

  21. Selectin (P-selectin and L-selectin) 【J. Clin. Invest. 112:853–862 (2003)】

  22. 2 【Blood 2007 110: 1723-1729】

  23. Tissue Factor (TF) • TF-rich tumor surface and TF-positive, Tumor-derived microparticle • Correlation between elevated TF and VTE

  24. TF-positive, Tumor-derived Microparticle (TMP) Phosphatidylserine negatively-charged phospholipids Selectinligand 【Blood. 2013;122(11):1873-1880】

  25. 3 【Blood 2007 110: 1723-1729】

  26. Cysteine Proteinase • directly activated factor X in the absence of factor VII

  27. 4 【Blood 2007 110: 1723-1729】

  28. Tumor Hypoxia • increase the expression of genes that facilitate coagulation, including tissue factor and plasminogen activator inhibitor type 1 (PAI-1)

  29. 5 【Blood 2007 110: 1723-1729】

  30. Oncogene Activation • MET oncogene involve up-regulation of PAI-1 and cyclooxygenase-2 (COX-2) genes

  31. 【Blood 2007 110: 1723-1729】

  32. Outline • History • Epidemiology • Pathogenesis • Thromboprophylaxis

  33. The increasing incidence of VTE 【Blood 2013 122: 1712-1723】

  34. VTE increase mortality prospective follow-up of >26000 subjects Tromsø study, prospective follow-up of >26000 subjects 【Blood 2013 122: 1712-1723】

  35. VTE related cancer mortality 1 2 2 【J ThrombHaemost 2007; 5: 632–4.】

  36. Symptomatic VTE for LMWH vs placebo NNT = 60 【Cochrane Database Syst Rev. 2012 Feb 5;2】

  37. Major bleeding for LMWH vsplacebo 【Cochrane Database Syst Rev. 2012 Feb 5;2】

  38. Risk Assessment Models negative predictive value of 98.5%at the cutoff point for high risk (>=3) 【Blood 2013 122: 2011-2018】

  39. D-dimer and P-selectin Vienna Cancer and Thrombosis Study (CATS) D-dimer soluble P-selectin 【Blood 2008 112: 2703-2708】

  40. Risk Assessment Models 【Blood 2013 122: 2011-2018】

  41. Risk Assessment Modelsin Taiwan population 【ThrombHaemost 2012; 108: 225–235】

  42. Prophylaxis or Not

  43. ？ Prophylaxis or Not

  44. ？ Prophylaxis or Not

  45. Conclusions • Cancer increased risk of VTE, especially advanced stage • The pathogenesis included mucin, tissue factor, and others • VTE increased mortality • Thromboprophylaxis is an issue, especially in high risk group

  46. Thanks for your attention

More Related